CAPECITABINE (Capecitabine) Nursing Considerations

What is the generic name?

CAPECITABINE

What is the Trade Name for CAPECITABINE?

Capecitabine

What are the Indications for CAPECITABINE?

• 1 INDICATIONS AND USAGE Capecitabine tablets are a nucleoside metabolic inhibitor with antineoplastic activity indicated for: ‚Ä¢ Adjuvant Colon Cancer ( 1.1 ) ‚Ä¢ Patients with Dukes‚Äô C colon cancer ‚Ä¢ Metastatic Colorectal Cancer ( 1.1 ) ‚Ä¢ First-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred ‚Ä¢ Metastatic Breast Cancer ( 1.2 ) ‚Ä¢ In combination with docetaxel after failure of prior anthracycline-containing therapy ‚Ä¢ As monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen 1.1 Colorectal Cancer ‚Ä¢ Capecitabine tablets are indicated as a single agent for adjuvant treatment in patients with Dukes‚Äô C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. Capecitabine tablets were non-inferior to 5-fluorouracil and leucovorin (5-FU/LV) for disease-free survival (DFS). Physicians should consider results of combination chemotherapy trials, which have shown improvement in DFS and OS, when prescribing single-agent capecitabine tablets in the adjuvant treatment of Dukes‚Äô C colon cancer. ‚Ä¢ Capecitabine tablets are indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone. A survival benefit over 5-FU/LV has not been demonstrated with capecitabine tablets monotherapy. Use of capecitabine tablets instead of 5-FU/LV in combinations has not been adequately studied to assure safety or preservation of the survival advantage. 1.2 Breast Cancer ‚Ä¢ Capecitabine tablets in combination with docetaxel are indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. ‚Ä¢ Capecitabine tablets monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated (e.g., patients who have received cumulative doses of 400 mg/m 2 of doxorubicin or doxorubicin equivalents). Resistance is defined as progressive disease while on treatment, with or without an initial response, or relapse within 6 months of completing treatment with an anthracycline-containing adjuvant regimen.

References: https://open.fda.gov/